Endocardial border delineation capability of a novel multimodal polymer-shelled contrast agent by Malin K Larsson et al.
CARDIOVASCULAR 
ULTRASOUND
Larsson et al. Cardiovascular Ultrasound 2014, 12:24
http://www.cardiovascularultrasound.com/content/12/1/24RESEARCH Open AccessEndocardial border delineation capability of a
novel multimodal polymer-shelled contrast agent
Malin K Larsson1*, Matilda Larsson1,2, Greg Nowak3, Gaio Paradossi4, Lars-Åke Brodin1,3, Birgitta Janerot Sjöberg1,3,5,
Kenneth Caidahl2,5 and Anna Bjällmark1,2Abstract
Background: A novel polymer-shelled contrast agent (CA) with multimodal and target-specific potential was
developed recently. To determine its ultrasonic diagnostic features, we evaluated the endocardial border delineation
as visualized in a porcine model and the concomitant effect on physiological variables.
Methods: Three doses of the novel polymer-shelled CA (1.5 ml, 3 ml, and 5 ml [5 × 108 microbubbles (MBs)/ml])
and the commercially available CA SonoVue (1.5 ml [2–5 × 108 MBs/ml]) were used. Visual evaluations of ultrasound
images of the left ventricle were independently performed by three observers who graded each segment in a
6-segment model as either 0 = not visible, 1 = weakly visible, or 2 = visible. Moreover, the duration of clinically useful
contrast enhancement and the left ventricular opacification were determined. During anesthesia, oxygen saturation,
heart rate, and arterial pressure were sampled every minute and the effect of injection of CA on these physiological
variables was evaluated.
Results: The highest dose of the polymer-shelled CA gave results comparable to SonoVue. Thus, no significant
difference in the overall segment score distribution (2-47-95 vs. 1-39-104), time for clinically sufficient contrast
enhancement (20–40 s for both) and left ventricular overall opacification was found. In contrast, when comparing
the endocardial border delineation capacity for different regions SonoVue showed significantly higher segment
scores for base and mid, except for the mid region when injecting 1.5 ml of the polymer-shelled CA. Neither high
nor low doses of the polymer-shelled CA significantly affected the investigated physiological variables.
Conclusions: This study demonstrated that the novel polymer-shelled CA can be used in contrast-enhanced
diagnostic imaging without influence on major physiological variables.
Keywords: Contrast agent, Echocardiography, Endocardial border delineation, Microbubbles, Polyvinyl alcohol,
Porcine, UltrasoundBackground
Intravenously injectable contrast agents (CA) consisting
of gas-filled microbubbles (MBs) with a mean diameter
of 2–5 μm can be used for improved image quality dur-
ing ultrasound examinations, which results in diagnostic
benefits. An ideal ultrasound CA must be biocompatible,
stable during image acquisition, and circulate without
causing obstructions or negative physiological effects. In
addition, it should have the ability to increase backscatter-
ing efficiency when exposed to an acoustic field. In 1968,* Correspondence: malinl@sth.kth.se
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was described [1]. At that time, fragile free-air MBs with a
short lifetime of a few seconds were used. Since then,
more stable CAs have been developed by encapsulating a
low-solubility gas within a stabilizing shell [2]. In parallel,
the development of specific ultrasound contrast pulse
sequences, which use the nonlinear response generated by
the MBs when exposed to acoustic pressure, has further
improved the possibility of successfully using these CAs
during ultrasound examinations [3,4].
Although commercially available ultrasound CAs are
relatively stable and used in various diagnostic procedures,
there is still a need for improvement and extended applic-
ability. One such example is targeted imaging, whichLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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flammatory tissue. Local deposition of drugs might also be
performed using a target-specific and drug-loaded CA.
Moreover, increased diagnostic efficiency and accuracy
can be achieved when using a multimodal CA, which
supports hybrid imaging by applying two or more modal-
ities to produce anatomical and functional information
simultaneously.
A novel polymer-shelled CA with high mechanical and
chemical stability was developed recently [5]. Further to
its ultrasound properties, it also supports targeted and
multimodal imaging (ultrasound, magnetic resonance
imaging, and emission imaging) because the chemical
versatility of its shell surface enables attachment of dif-
ferent substances such as antibodies, superparamagnetic
iron oxide nanoparticles (SPIONs) and technetium [6-9].
Even though these new possibilities have the potential to
lead to new methodologies and approaches for noninva-
sive diagnosis, it is important that the diagnostic features
in contrast-enhanced ultrasound are preserved. The aim
of this study was therefore to investigate the left ventricu-
lar endocardial border delineation capability in ultrasound
images of a porcine model when using the polymer-
shelled CA. In addition, the effect of CA injection on
physiological variables was studied.Methods
To assess the endocardial border delineation capability
of the unmodified air filled polymer-shelled CA, a com-
parative study, including a commercially available lipid
monolayer membrane-shelled CA containing sulfur hexa-
fluoride (SonoVue, Bracco Imaging, Milan, Italy), was per-
formed using a porcine model. Visual interpretations were
performed by independent observers who were blinded
to CA type and dose. Additionally, semiautomatic seg-
mentation was applied to provide information regarding
the uniformity of left ventricular opacification.Table 1 Characteristics of the ultrasound settings used
for the two contrast agents
CA Contrast sequence Frequency
(MHz)
MI
Polymer-shelled CA Power pulse inversion 1.6/3.2 0.89–0.93
SonoVue Power modulation 1.6/3.2 0.39
CA = contrast agent, MI = mechanical index.Animals
The study protocol was approved by the local Ethics
Committee for Animal Experiments in Stockholm,
Sweden. Eight crossbred (Swedish Landrace, Yorkshire,
or Hampshire) littermate female open-chest pigs with
a body weight of 34.6 ± 3.1 kg were included in the
study. The pigs were fasted overnight before surgery
with free access to water. Anesthesia was induced with
an intramuscular injection of fentanyl and atracurium
before endotracheal intubation. Subsequently anesthesia
was maintained with 1–2% isoflurane ventilation and was
augmented with fentanyl and atracurium intravenous
injection when required. Animals were continuously
monitored with ECG, pulse oximetry, and invasive ar-
terial blood pressure. Liometacen (Promedica, Parma,Italy) was intravenously injected (10 mg/kg, 5 mg/kg/h)
to prevent pulmonary and systemic hypertension [10].
Contrast agents
The novel polymer-shelled contrast agent is produced
by cross-linking of synthesized polyvinyl alcohol at the
air-water interface during high-shear stirring with an
Ultra Turrax (IKA, Staufen, Germany) stirrer at 8000 rpm
[5], resulting in air-filled MBs with a mean diameter of
4.6 μm± 0.4 μm and a shell thickness of 0.4 μm [11]. In
each pig, three bolus doses (1.5 ml, 3 ml, and 5 ml) of
the polymer-shelled CA [5 × 108 MBs/ml] and 1.5 ml of
SonoVue [2–5 × 108 MBs/ml] were manually injected
through a central venous catheter placed in the external
jugular vein, at a speed of approximately 0.75 ml/s. In
addition, a 4 ml flush of 0.9% saline followed each CA
injection. The subsequent CA injection started after
about 10 minutes when no contrast enhancement could
be observed in the left ventricle. SonoVue and the dif-
ferent doses of the polymer-shelled CA were injected in
a randomized order in each animal.
Image acquisition
For ultrasound imaging, a commercially available clinical
ultrasound machine was used (iE33; Philips Healthcare,
Best, The Netherlands). Ultrasound-imaging settings such
as contrast sequences, frequency, mechanical index (MI),
focus depth, and gain were individually optimized for each
CA according to in vitro [8] and in vivo pilot studies (see
Table 1). ECG-triggered ultrasound images from the apical
two-chamber view were acquired by an experienced echo-
cardiographer at end-systole. The image acquisition was
stopped when no or very low contrast enhancement was
visually observed in the left ventricle.
Visual evaluation
For each injection, the obtained image series were divided
in time intervals of 20 seconds, starting when inflow of
CA into the left ventricle was observed. From each time
interval, the image with the highest and most homoge-
neous contrast enhancement was selected for further
analysis using a Q-Lab workstation (Philips Healthcare,
Best, The Netherlands). Among these images, experi-
enced observers (n = 3), who were blinded to CA type
and dose, visually selected the image with best potential
for endocardial border delineation. This was done
Figure 1 The 6-segment model used for image analysis. The
endocardial border delineation for each segment was graded as
0 = not visible, 1 = weakly visible, or 2 = visible.
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delineation of the selected image was evaluated by the
observers using a 6-segment model (see Figure 1). Every
segment was graded as 0 = not visible, 1 = weakly visible,
or 2 = visible. Furthermore, the duration of clinically
useful contrast enhancement was evaluated by the three
observers visually (while still blinded to dose and CA
type), and the mean time was calculated for each dose
and injection.
Semiautomatic delineation
Segmentation software based on level-set developed in
MATLAB (MathWorks, Natick, MA, USA) [12,13] was
used to evaluate semiautomatic border definition in the
ultrasound images. Because there is no clear difference
in signal intensity between a contrast-enhanced atrium
and a contrast-enhanced ventricle, the segmentation soft-
ware was modified for the current application by allowing
manual definition of the atrioventricular plane. Further-
more, the number of iterations (2500) and Caselles algo-
rithm [13] were selected by initial testing to fit the current
application.
The same set of images as selected by the observers for
the visual evaluation was employed in the semiautomaticTable 2 The segment visibility score distribution for each dos
CA (injected dose) All segments
(n = 144) (
0 1 2 0
SonoVue (1.5 ml) 1 39 104 1
Polymer-shelled CA (1.5 ml) 4 49 91 1
(P < 0.05)
Polymer-shelled CA (3 ml) 12 48 84 3
(P < 0.001)
Polymer-shelled CA (5 ml) 2 47 95 2
(NS)
A significant difference in segment scores between SonoVue and the polymer-shell
by segment and pig using a Wilcoxon signed-rank test).
CA = contrast agent (0 = not, 1 = weakly, 2 = visible).delineation. In these images, an initial elliptical region
(with an area of approximately a quarter of the total area
of the left ventricle) was manually placed in the center of
the left ventricle and thereafter the automated delineation
was initiated. In addition, the experienced observers
performed manual delineation of the endocardial border
by pointing out 20 border points in the image followed
by spline interpolation to delineate the reference border.
The overlap between the reference border and semiau-
tomatic delineation was evaluated by calculating the
Dice value (D) as:
D A; Bð Þ ¼ 2 ∣A ∩ B∣= ∣A∣þ ∣B∣ð Þ;
where A was the set from the semiautomated delineation
and B the set from the reference border. A higher Dice
value corresponded to a better delineation match between
the reference and semiautomatic delineation. A Dice value
of 1 corresponded to an ideal match.
Physiological data
During anesthesia, oxygen saturation (SaO2), heart rate,
and arterial pressure were sampled every minute. After
the final injection dose, data was exported and analyzed
offline.
Statistical analysis
The differences in overall segment score (n = 144) and in
segment score for different wall-regions (apical, mid,
and base, each n = 48) between SonoVue and the three
doses of the polymer-shelled CA were evaluated using a
Wilcoxon signed-rank test. The effect of injection of CA
on the physiological variables was evaluated by compar-
ing the relative difference between 3 minutes before and
after injection of each dose using a paired two-sided
Student t test (95% confidence interval). Furthermore, a
McNemar test was used to compare the Dice valuee and CA injected
Apical Mid Base
n = 48) (n = 48) (n = 48)
1 2 0 1 2 0 1 2
33 14 0 0 48 0 6 42
26 21 0 3 45 3 20 25
(NS) (NS) (P < 0.001)
27 18 3 4 41 6 17 25
(NS) (P < 0.05) (P < 0.001)
22 24 0 4 44 0 21 27
(NS) (P < 0.05) (P < 0.05)
ed CA is indicated by its P-value and a nonsignificant difference with NS (paired
Figure 2 Ultrasound contrast images of the porcine left ventricle. Injection of 1.5 ml of the polymer-shelled CA (A) and 1.5 ml of SonoVue (B).
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for three different Dice value intervals (<0.8; 0.8–0.9;
>0.9).Results
Visual evaluation
The segment score distribution for each dose and CA is
presented in Table 2. When considering all segments
within the left ventricle, there was no significant differ-
ence in segment score between the 5 ml injection of the
polymer-shelled CA and SonoVue, indicating no signifi-
cant difference in the overall capability of the endocar-
dial border delineation for the two CAs at these doses.
By comparison with SonoVue, significantly lower seg-
ment scores were obtained for the polymer-shelled CA
at doses lower than 5 ml.
When comparing segment scores for different wall-
regions (apical, mid, and base) within the left ventricle,
no significant difference in segment score was observed
for SonoVue or any of the polymer-shelled CA injections
for the apical region (Table 2). For the other two regions
(mid and base), SonoVue showed significantly better
performance than all three doses of the polymer-shelled
CA, with one exception in the mid region when inject-
ing 1.5 ml. Examples of ultrasound images obtained dur-
ing the examination for both CAs are shown in Figure 2.
According to the results from the observers, the longest
detectable time of clinical useful contrast enhancement
was obtained when injecting 5 ml of the polymer-shelled
CA and 1.5 ml SonoVue (see Table 3). The clinically useful
time periods of contrast enhancement for these twoTable 3 Time period of clinically useful contrast
enhancement after CA injection
CA (injected dose) Clinically useful time period
SonoVue (1.5 ml) 20–40 s
Polymer-shelled CA (1.5 ml) 0–20 s
Polymer-shelled CA (3 ml) 0–20 s
Polymer-shelled CA (5 ml) 20–40 s
CA = contrast agent.injections were in the range of 20–40 seconds, while the
first time interval (0–20 seconds) was observed for the
other two injections.
Semiautomatic delineation
Figure 3 shows the Dice value distribution (<0.8; 0.8–
0.9; >0.9) for all doses (n = 24). As can be seen, similar
distribution of Dice values were obtained for 1.5 ml
SonoVue and the 5 ml injection of the polymer-shelled
CA. By contrast with the lower doses (1.5 ml and 3 ml)
of the polymer-shelled CA, these two doses had a distri-
bution shifted towards the highest Dice value interval
(>0.90), which indicated a better match with the refer-
ence delineation. The McNemar test further indicated
that there was a significant difference in distribution for
the highest Dice value between the lower doses and Sono-
Vue. Figure 4 illustrates the difference in homogeneity of
the left ventricular opacification when injecting 1.5 ml
(Figure 4A), 3 ml (Figure 4B), and 5 ml (Figure 4C) of the
polymer-shelled CA.
Physiological data
Table 4 presents the mean baseline values for the inves-
tigated physiological variables obtained before CA injec-
tion. No significant change in SaO2, heart rate, or mean
arterial pressure for any dose of the polymer-shelled CA
was observed. Table 5 shows the mean percentage differ-
ences before and after CA injection between the physio-
logical variables.
Discussion
The use of CA during ultrasound examinations improves
endocardial border delineation in patients with suboptimal
ultrasound images [14-16]. This enables a more accurate
assessment of left ventricular wall motion, wall-thickening
abnormalities, volume measurements, and calculation of
ejection fraction. These variables are crucial factors for
characterization and prognosis of cardiac diseases such as
myocardial ischemia and myocardial infarction [17,18].
This study showed that the performance for delinea-
tion of the endocardial border of 5 ml of the novel
polymer-shelled CA was comparable to 1.5 ml of the
Figure 3 Dice value distribution. The number of delineations
(3 observers x 8 pigs) for each dose (1.5 ml SonoVue; 1.5 ml, 3 ml, or
5 ml polymer-shelled CA) distributed over Dice value ranges of <0.80,
0.80–0.90, and >0.90. A higher Dice value corresponds to a better
match with the reference delineation. *Significant difference (P < 0.05)
in Dice value distribution compared with SonoVue.
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included similar values of overall segment scores and
time periods for clinically sufficient contrast enhance-
ment as rated by the observers (see Tables 2 and 3). In
addition, the results from the semiautomatic segmenta-
tion software were in agreement with this, showing
equal distribution of Dice values for SonoVue and the
5 ml injection of the polymer-shelled CA, which indi-
cated a uniform left ventricular opacification for the two
CAs. Nevertheless, this study also implies that the
polymer-shelled CA does not have the same backscatter-
ing efficiency as SonoVue because a larger volume is
needed to obtain similar contrast enhancement. The dif-
ference in shell thickness between the two types of CAs,
where the polymer-shelled CA has a thicker and stiffer
shell than SonoVue [11,19], is suggested to be the cause
of this difference. A thicker shell is less flexible and has
considerable damping, which causes a reduction in MB
radius oscillation, and therefore a decrease in the nonlin-
ear response [20]. Despite this, the advantage of the
polymer-shelled CA is that its shell can be decorated by
different substances to enable multimodal and targeting
imaging. Improvements in designing ultrasound contrastFigure 4 Illustration of the results obtained from the semiautomatic d
yellow line represents the semiautomatic delineation. (A) 1.5 ml polymer-shel
(C) 5 ml polymer-shelled CA, Dice value = 0.95.pulse sequences optimized for the polymer-shelled CA
could increase its diagnostic capabilities. On the other
hand, results from this study show that a high concentra-
tion of the polymer-shelled CA is applicable from a purely
echocardiographic point-of-view when using commercially
available contrast sequences.
This study employed an unmodified polymer-shelled
CA to obtain an indication of the approximate outcome
in standard contrast-enhanced echocardiography. Attach-
ment of ligands or incorporation of therapeutic gases or
drugs may alter our ability to visualize the CA depending
on the properties of the incorporated substance. This has
been observed in both single-element set-ups [21,22] and
in phantom studies using clinical ultrasound systems [8],
where the latter showed that the introduction of SPIONs
to the polymer-shelled CA increases backscattering effi-
ciency when applying the same image-acquisition settings
as in the present study. Even though unmodified MBs
were used in the present study, the results give an indi-
cation of what can be expected when performing similar
examinations with modified MBs.
A possible advantage of the polymer-shelled CA com-
pared with SonoVue in the context of endocardial border
delineation is the fact that the polymer-shelled CA toler-
ates higher pressure amplitudes before the MBs rupture.
When performing contrast-enhanced imaging with thin-
shelled CA such as SonoVue, there is a trade-off between
visualization of deep structures of the heart, where high-
pressure amplitudes are optimal, and visualization of near-
field regions, where low-pressure amplitudes are optimal,
because high-pressure amplitudes rupture the MBs in the
near-field regions. Thus, the polymer-shelled CA might be
expected to allow better visualization of both the apical
and the basal regions because higher MI was used for
the polymer-shelled CA (MI = 0.89–0.93) compared
with SonoVue (MI = 0.39). However, this was not seen
in the present study. One possible explanation is that the
ultrasound beam was attenuated when high-pressure am-
plitudes in combination with a large dose of the polymer-elineation. The red line represents the reference delineation and the
led CA, Dice value = 0.61; (B) 3 ml polymer-shelled CA, Dice value = 0.82;
Table 4 The mean value for the physiological variables
obtained before CA injection
SaO2 Heart rate Mean arterial pressure
(%) (bpm) (mmHg)
98 ± 1.5 93 ± 14 78 ± 13
CA = contrast agent, SaO2 = oxygen saturation.
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aging depth [23]. Another possible explanation could be
that trigged imaging was used. When employing trigged
imaging for SonoVue, MI can be higher than during con-
tinuous imaging which in turn optimizes the visualization
of the base.
The scoring results from the three observers were
unanimous. All observers indicated the same ranking of
the different CA doses, where SonoVue and the 3 ml in-
jection of the polymer-shelled CA received the highest
and the lowest segment scores by each observer, respect-
ively. However, the segment scores for each CA dose dif-
fered between the observers. In general, the same
observer reported the highest segment scores, while the
lowest segment scores were observed by another obser-
ver. This consistency among the observers indicates that
the model used to evaluate the CAs is robust. Because
the semiautomatic delineation was evaluated against the
manual reference, no objective analysis was obtained. All
observers had extensive experience analyzing cardiac
contrast-enhanced ultrasound images and their reference
could therefore be used as the adequate delineation of
the left ventricle. A limitation of the analysis is that
intermittent imaging was used, which implied that the
observer could not step back and forward in the image
sequence when some parts of the endocardium were not
fully visible because of, e.g., attenuation effects. This might
have produced lower segment scores than if continuous
imaging had been employed. Moreover, the ability to
evaluate regional wall motion or to fully optimize left ven-
tricular volume measurements was not possible with these
settings. Nevertheless, by employing intermittent imaging
in this study, visual evaluation and semiautomatic delinea-
tion could be performed under equivalent conditions. The
ability of the novel polymer-shelled CA to detect cardiacTable 5 Physiological parameters before and after CA injectio
CA (injected dose) SaO2
(%)
SonoVue (1.5 ml) 0% ± 0
Polymer-shelled CA (1.5 ml) 0% ± 0
Polymer-shelled CA (3 ml) 0% ± 0
Polymer-shelled CA (5 ml) 0% ± 0
CA = contrast agent, SaO2 = oxygen saturation. Mean percentage difference ± standabnormalities is a secondary step and will be evaluated in
future work.
The performance of semiautomatic delineation pro-
vides information about the ability to delineate the
endocardial border and the uniformity of left ventricu-
lar opacification, which is seen clearly in Figure 4A-B.
A homogenous and persistent left ventricular opacifi-
cation is of great importance in contrast-enhanced
echocardiography because previous studies have shown
that a complete left ventricular opacification results
in up to 95% improvement in endocardial border
resolution [24].
Even though a relatively large dose of the CAs were
injected in each pig, no significant variation in the
physiological variables was seen during the experiment,
which indicated a stable anesthesia procedure and no
untoward hemodynamic effect of CA injections. On the
other hand, a rather large CA dose could increase the
risk of CA saturation after repeated injections. By ran-
domizing the order of the CA injections in each pig, this
risk was minimized. Furthermore, recovery periods be-
tween injections were also present. It was not possible to
evaluate whether there was a difference when low doses
of CA were distributed before or after high doses be-
cause there were relatively few injections. Moreover,
minor contrast peaks during periods between the injec-
tions were not observed, which indicated the absence of
CAs in the circulation.Conclusions
This study demonstrated that the novel polymer-shelled
CA can be useful in contrast-enhanced diagnostic im-
aging for endocardial border delineation. The ability of
the novel polymer-shelled CA to delineate endocardial
border was comparable to SonoVue when injecting a
high dose. This was shown by similar distribution for
overall segment scores from visual observations, time for
clinically sufficient contrast enhancement, and the same
ability for semiautomatic delineation of the left ventricle.
In addition, injections of the polymer-shelled CA did
not significantly affect SaO2, heart rate, or arterial pres-
sure. To evaluate its diagnostic capacity further, studiesn
Heart rate Mean arterial pressure
(bpm) (mmHg)
0% ± 1 5% ± 9
0% ± 2 −2% ± 2
−4% ± 8 −1% ± 4
−2% ± 3 2% ± 3
ard deviation.
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targeted imaging are warranted.
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